Ardian has closed its eighth global secondaries fund with $19 billion in commitments, representing the largest-ever vehicle raised for the strategy. The total includes $5 billion for co-investment.
It continues a steady increase in Ardian’s fund sizes through the vintages. The firm crossed the $10 billion threshold with Fund VI in 2014 then closed Fund VII at $14 billion two years later. Total...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.